ArticleCancer management and research2018
Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma.
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 60 citations in OpenAlex.
- Recent progress of dendritic cell-derived exosomes in tumor immunotherapy.Investigational new drugs · 2026Review
- Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms.Small science · 2025Review
- Exosome-Based Theranostic for Gastrointestinal Cancer: Advances in Biomarker Discovery and Therapeutic Engineering.Small methods · 2025Review
- The role of exosomes in bladder cancer immunotherapy.Journal of the National Cancer Center · 2025Review
- The Application of Dendritic Cells Vaccines in Tumor Therapy and Their Combination with Biomimetic Nanoparticles.Vaccines · 2025Review
- Potential and development of cellular vesicle vaccines in cancer immunotherapy.Discover oncology · 2025Review
- Exosomes: their role and therapeutic potential in overcoming drug resistance of gastrointestinal cancers.Frontiers in oncology · 2025Review
- Protein cargo in extracellular vesicles as the key mediator in the progression of cancer.Cell communication and signaling : CCS · 2024Review
- Communicator Extraordinaire: Extracellular Vesicles in the Tumor Microenvironment Are Essential Local and Long-Distance Mediators of Cancer Metastasis.Biomedicines · 2023Review
- Extracellular Vesicles in Hepatocellular Carcinoma: Progress and Challenges in the Translation from the Laboratory to Clinic.Medicina (Kaunas, Lithuania) · 2023Review
- Risk factors of primary liver cancer initiation associated with tumour initiating cell emergence: novel targets for promising preventive therapies.eGastroenterology · 2023Review
- Exosomes from Ub‑HBcAg‑overexpressing dendritic cells induce T‑lymphocyte differentiation and enhance cytotoxic T‑lymphocyte activity.Experimental and therapeutic medicine · 2023Article
- The Role of Alpha-Fetoprotein (AFP) in Contemporary Oncology: The Path from a Diagnostic Biomarker to an Anticancer Drug.International journal of molecular sciences · 2023Review
- Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles.Frontiers in molecular biosciences · 2023Review
- Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine.Frontiers in pharmacology · 2023Review
- The mononuclear phagocyte system in hepatocellular carcinoma.World journal of gastroenterology · 2022Review
- Extracellular vesicles and particles impact the systemic landscape of cancer.The EMBO journal · 2022Review
- Review
- Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications.Biomarker research · 2022Review
- Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDendritic cell (DC)-derived exosomes (Dexs) have been proved to induce and enhance antigen-specific T cell responses
methodsIn this study, human peripheral blood-derived DCs were loaded with recombinant adeno-associated viral vector (rAAV)-carrying alpha-fetoprotein (
resultsOur findings showed that Dexs were effective to stimulate naive T cell proliferation and induce T cell activation to become antigen-specific cytotoxic T lymphocytes (CTLs), thereby exhibiting antitumor immune responses against HCC. In addition, Dex-sensitized DC precursors seemed more effective to trigger major histocompatibility complex class I (MHC I)-restricted CTL response and allow DCs to make full use of the minor antigen peptides, thereby maximally activating specific immune responses against HCC.
conclusionIt is concluded that Dexs, which combine the advantages of DCs and cell-free vectors, are promising to completely, or at least in part, replace mature DCs (mDCs) to function as cancer vaccines or natural antitumor adjuvant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.